Prostate Cancer News

CancerConnect prostate cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of prostate cancer research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of prostate cancer treatment and survivorship.

Share

Prostate Cancer News


Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer (June 18, 2014)

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared... Continue Reading

Xtandi Found to Delay Need for Chemotherapy in Metastatic Prostate Cancer Patients (June 16, 2014)

In results of a phase III trial reported at the 2014 American Society of Clinical Oncologists, treatment with Xtandi® (enzalutamide) was found to significantly delay the need for chemotherapy in metastatic... Continue Reading

Genomic Health Demonstrates the Importance of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers (June 9, 2014)

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene... Continue Reading

Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients (June 3, 2014)

In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate cancer patients was found to extend... Continue Reading

New biopsy method shows prostate cancers considered ‘low risk’ may be anything but (May 22, 2014)

More and more men who have low-risk prostate cancers are forgoing treatment and opting for active surveillance, in which their tumors are closely monitored with PSA tests, digital rectal exams and ultrasounds... Continue Reading

Radical Prostatectomy Offers Long-Term Benefit Over Watchful Waiting in Early Prostate Cancer (May 22, 2014)

Researchers in Sweden recently reported in The New England Journal of Medicine that radical prostatectomy continues to show long-term benefits over watchful waiting in early prostate cancer. Follow up... Continue Reading

Recent Studies Find Oncotype DX® Can Reliably Predict Risk of Aggressive Prostate Cancer (May 22, 2014)

Based on findings from three separate studies, it appears that the 17-gene Oncotype DX® Genomic Prostate Score (GPS) can help predict disease aggressiveness in prostate cancer at the time of diagnosis... Continue Reading

Longest Follow-Up to Date Shows Active Surveillance is Safe and Feasible (April 23, 2014)

Results from the longest follow-up to date of active surveillance in patients with favorable or intermediate-risk prostate cancer indicate that the approach is safe and feasible for as long as 20 years... Continue Reading

Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (April 21, 2014)

Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 European... Continue Reading

Radical Prostatectomy Shows Significant Long-Term Benefit in Early Prostate Cancer (March 18, 2014)

Extended follow-up of the Scandinavian Prostate Cancer Group-4 trial (SPCG-4) has confirmed that radical prostatectomy is associated with a substantial reduction in mortality among men with early prostate... Continue Reading

More Prostate Cancer News

Latest Prostate Cancer News By Stage


Screening and Prevention

Prostate Cancer Screening Can Take a Toll on Quality of Life (December 19, 2012)

Screening for prostate cancer carries some risks and can affect quality of life. Considering these risks is important when making the decision about whether to be screened. The results of a study that assessed both the potential benefits of screening... Continue Reading

PSA Testing May Be Appropriate for Some Men (July 25, 2012)

The American Society of Clinical Oncology (ASCO) has released a Provisional Clinical Opinion (PCO) suggesting that that men with a longer life expectancy—those with at least 10 more years to live—discuss with their physician the potential risks and... Continue Reading

Side Effects of Prostate Cancer Treatment Persist Long-Term (July 5, 2012)

Men who are treated for prostate cancer may continue to suffer from side effects 10 years after treatment, according to the results of a study published in the Journal of Clinical Oncology. Each year in the United States, more than 192,000 men are diagnosed... Continue Reading

Number of Cancer Survivors Will Grow to 18 Million by 2022 (June 25, 2012)

There will be nearly 18 million cancer survivors in the United States by 2022, according to a report by the American Cancer Society and the National Cancer Institute: Cancer Treatment & Survivorship Facts & Figures[1] and an accompanying journal... Continue Reading

Prostate Screening Not Recommended for Older Men (June 1, 2012)

The U.S. Preventive Services Task Force (USPSTF) recently drafted a grade D recommendation against prostate-specific antigen (PSA) screening for prostate cancer; however, it is unclear how this will affect screening practices since their previous recommendation... Continue Reading

More Screening and Prevention

Early Stage I-II (A-B)

Genomic Health Demonstrates the Importance of Utilizing Multiple Biological Pathways to Predict Tumor Behavior in Prostate and Renal Cancers (June 9, 2014)

REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ – Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX® test and a new 16-gene panel to predict disease aggressiveness and clinical... Continue Reading

Radical Prostatectomy Offers Long-Term Benefit Over Watchful Waiting in Early Prostate Cancer (May 22, 2014)

Researchers in Sweden recently reported in The New England Journal of Medicine that radical prostatectomy continues to show long-term benefits over watchful waiting in early prostate cancer. Follow up studies in the Scandinavian Prostate Group Cancer... Continue Reading

Recent Studies Find Oncotype DX® Can Reliably Predict Risk of Aggressive Prostate Cancer (May 22, 2014)

Based on findings from three separate studies, it appears that the 17-gene Oncotype DX® Genomic Prostate Score (GPS) can help predict disease aggressiveness in prostate cancer at the time of diagnosis and therefore help physicians choose appropriate... Continue Reading

Longest Follow-Up to Date Shows Active Surveillance is Safe and Feasible (April 23, 2014)

Results from the longest follow-up to date of active surveillance in patients with favorable or intermediate-risk prostate cancer indicate that the approach is safe and feasible for as long as 20 years after diagnosis. These results were presented at... Continue Reading

Radical Prostatectomy Shows Significant Long-Term Benefit in Early Prostate Cancer (March 18, 2014)

Extended follow-up of the Scandinavian Prostate Cancer Group-4 trial (SPCG-4) has confirmed that radical prostatectomy is associated with a substantial reduction in mortality among men with early prostate cancer. These results were published in the New... Continue Reading

More Early Stage I-II (A-B)

Locally Advanced Stage III (C)

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer (June 18, 2014)

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

Metformin May Improve Survival in Diabetic Men with Prostate Cancer (September 4, 2013)

Diabetic men with prostate cancer lived significantly longer and were significantly less likely to die of prostate cancer when treated with metformin, an insulin-lowering drug, according to the results of a study published in Journal of Clinical Oncology. Prostate... Continue Reading

ASTRO and AUA Issue Joint Guideline for Radiation After Prostate Surgery (June 18, 2013)

The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) have issued a joint guideline regarding the use of radiation therapy after prostatectomy. It marks the first time the two medical organizations—most responsible... Continue Reading

Genomic Test May Help Guide Prostate Cancer Treatment (May 13, 2013)

A new genomic test—the Oncotype DX® Prostate Cancer Test—measures the aggressiveness of prostate cancer and may help scores of men choose between immediate treatment or active surveillance. The test was shown to strongly predict aggressiveness of... Continue Reading

More Locally Advanced Stage III (C)

Metastatic Stage IV (D)

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer (June 18, 2014)

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in... Continue Reading

Xtandi Found to Delay Need for Chemotherapy in Metastatic Prostate Cancer Patients (June 16, 2014)

In results of a phase III trial reported at the 2014 American Society of Clinical Oncologists, treatment with Xtandi® (enzalutamide) was found to significantly delay the need for chemotherapy in metastatic prostate cancer patients previously treated... Continue Reading

Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients (June 3, 2014)

In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate cancer patients was found to extend overall survival by more than 13 months. The results... Continue Reading

Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (April 21, 2014)

Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 European Association of Urology (EAU) Congress in Stockholm,... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

More Metastatic Stage IV (D)

Refactory/Recurrent

Combination Hormone Therapy Appears Safe and Effective in Reducing Testosterone in Metastatic Prostate Cancer (June 18, 2014)

In a study presented at the 2014 American Society of Clinical Oncologists meeting, researchers reported that the use of two hormone blocking agents—Xtandi® (enzalutamide) and Zytiga® (abiraterone)—appeared safe and reduced testosterone levels in... Continue Reading

Taxotere Added to Hormone Therapy Improves Overall Survival by 13 Months in Metastatic Prostate Cancer Patients (June 3, 2014)

In a study conducted by researchers at the Dana-Farber Cancer Institute, Taxotere® (docetaxel) administered with androgen-deprivation therapy to metastatic prostate cancer patients was found to extend overall survival by more than 13 months. The results... Continue Reading

Xtandi Shows Significant Benefit in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (April 21, 2014)

Xtandi® (enzalutamide) showed significant survival benefit in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 European Association of Urology (EAU) Congress in Stockholm,... Continue Reading

High Incidence of Many Complications after Surgery or Radiation for Prostate Cancer (February 27, 2014)

Men who undergo surgery or radiation therapy for prostate cancer may face a variety of complications in addition to incontinence and erectile dysfunction—including high rates of hospitalization, urologic procedures, anal/rectal procedures, open surgeries,... Continue Reading

Xtandi Improves Survival in Chemotherapy-Naïve, Metastatic, Hormone-Refractory Prostate Cancer (February 19, 2014)

Xtandi® (enzalutamide) improved survival and reduced the risk of radiographic progression in men with chemotherapy-naïve, metastatic, hormone-refractory prostate cancer, according to the results of a study presented at the 2014 Genitourinary Cancers... Continue Reading

<More Refactory/Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Just another WordPress weblog
Facebook Twitter RSS